Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Mirum Pharmaceuticals, Inc.
MIRM
NASDAQ·Healthcare·Biotechnology·Mkt cap $6.0B
$123.88
▲ +2.84%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$49.01 - $125.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 145.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Focused pipeline targeting underserved rare liver disease markets with limited competition
- Oral drug formulations offering improved patient compliance versus existing alternatives
- Orphan drug designation providing regulatory advantages and market exclusivity periods
- Specialized expertise in cholestatic liver disease mechanisms and treatment development
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Moderate growth ahead
Regulatory approvals and commercialization of LIVMARLI across multiple indications
Value
Valuation data unavailable
Momentum
Hot
+27.9% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MIRM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 6, 2026
Reported EPS of -$13.43 vs -$0.75 consensus (-1690.7% surprise). Revenue of $159.9M vs $148.2M expected (+7.9%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-1690.7%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
+43%
+61%
+64%
+47%
+50%
+43%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$77.9M
$90.4M
$99.4M
$111.6M
$127.8M
$133.0M
$148.9M
$159.9M
Margins · last 8Q
Gross
—
Operating
—
Profit
-494.2%
Wall Street consensus
10 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$142.00
▲ +14.6% vs $123.88
Latest: HC Wainwright · Jun 15, 2026
8 analysts covering